NewAmsterdam Pharma
NAMS
22.13
-0.14
-0.63%
NewAmsterdam Pharma
US · NAMS
#2583 by market cap
Listed 1970
22.13
-0.14
-0.63%
Live - 5344 symbols - heartbeat 544s ago
· 2026-10-08 07:04
Pre-market
22.60
+2.12%
After-hours
22.52
+1.76%
Overnight
22.09
-0.18%
- Market cap
- 2.65B
- P/E (TTM)i
- -10.25
- P/Bi
- 4.19
- EPSi
- -1.72
- Div yieldi
- 0.00%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on NAMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 105.78% -1.22pp
- Institutions
- 246 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund44.05%
VC/PE Fund36.55%
Hedge Fund17.17%
Family Office/Trust2.58%
Public Company2.51%
Private Company2.10%
Individual/Insider0.89%
Sovereign Wealth Fund0.70%
Government Pension Fund0.12%
Top holders as of 2026-09-18
Frazier Life Sciences Management, LP
15.84% · 18.94M sh
Capital Research
11.67% · 13.95M sh
FMR
8.65% · 10.34M sh
RA Capital Management, L.P.
7.99% · 9.55M sh
Forbion Capital Partners B.V.
7.10% · 8.49M sh
Deerfield Management Company, L.P.
3.57% · 4.26M sh
Viking Global Investors LP
3.52% · 4.20M sh
Bain Capital Life Sciences Investors, LLC
3.18% · 3.81M sh
Maverick Capital, Ltd.
2.73% · 3.27M sh
Duquesne Family Office LLC
2.57% · 3.07M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.84% |
| Michael Davidson | CEO, President, Executive Board Member & Director | 0.77% |
| Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | 0.06% |
| Hilde van der Kamp | Independent Non-Executive Director | 0.03% |
| Douglas Kling | Chief Operating Officer | 0.01% |
| Mayur Somaiya | Chief Financial Officer | 0.01% |
| Adele M. Gulfo | Independent Director | 0.00% |
| Louise Kooij | Interim Chief Financial Officer | 0.00% |
| Louis Lange | Non-Executive Director | 0.00% |
| Mark McKenna | Non-Executive Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -50,246 | $25.03 |
| 2026-09-13 | Michael Davidson | CEO, President, Executive Board Member & Director | Open Market Acquisition | +10,000 | $22.65 |
| 2026-09-03 | John Smither | Independent Director | Open Market Disposition | -1,600 | $25.32 |
| 2026-08-31 | Robert Gunning | Vice President | Other Acquisition | +3,200 | -- |
| 2026-08-31 | Robert Gunning | Vice President | Other Derivative Acquisition | +14,000 | $24.92 |
| 2026-08-24 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -250,000 | -- |
| 2026-08-23 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -125,000 | $26.91 |
| 2026-07-19 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -105,000 | $11.17–31.71 |
| 2026-06-21 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -40,000 | $10.90–30.73 |
| 2026-05-25 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -65,000 | $10.00–35.69 |
| 2026-03-10 | Louis Lange | Non-Executive Director | Open Market Disposition | -44,619 | $30.41–31.23 |
| 2026-03-08 | Louis Lange | Non-Executive Director | Derivative Exercise and Retained | +44,619 | $11.50 |
| 2026-03-08 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -300,000 | $30.29–30.32 |
| 2026-03-05 | Louis Lange | Non-Executive Director | Open Market Disposition | -28,186 | $29.41 |
| 2026-03-01 | Michael Davidson | CEO, President, Executive Board Member & Director | Derivative Exercise and Sale | -443,707 | $33.25 |
| 2026-03-01 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -300,000 | $31.18 |
| 2026-02-25 | Michael Davidson | CEO, President, Executive Board Member & Director | Derivative Exercise and Sale | -306,293 | $33.63–36.68 |
| 2026-02-23 | Michael Davidson | CEO, President, Executive Board Member & Director | Intent to Sell (Form 144) | -750,000 | $36.17 |
| 2026-02-19 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Open Market Disposition | -45,481 | $35.00–35.46 |
| 2026-01-27 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -72,428 | $10.90–32.62 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:04:28 · For reference only, not investment advice and not tailored to your situation.